Analysis of the Swiss chemists’ statement saying most CBD cannabis products fail to meet standards. However, it only concerns food and veterinary products.
| |

Analysis of the Swiss chemists’ statement saying most CBD cannabis products fail to meet standards. However, it only concerns food and veterinary products.

ByCédric Heeb

On February 1st 2022, the Swiss Association of Cantonal Chemists, announced in a press release that, in Switzerland, the vast majority of products sold containing the cannabis extract cannabidiol (CBD) do not meet legal requirements. It was relayed across many media channels, such as swissinfo stating that Most CBD cannabis products fail to meet standards. However, these findings do not apply to the medical/therapeutic cannabis.

Analysis of the new publication regarding cannabis compound CBD stopping coronavirus.
|

Analysis of the new publication regarding cannabis compound CBD stopping coronavirus.

ByNikola NOWOTARSKA

Several recent laboratory studies of cannabidiol, or CBD, have shown promising results in the context of prevention the coronavirus infection.  The study performed by the team of Marsha Rosner of the University of Chicago (USA) recently published evidence that CBD could block the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) responsible for COVID-19.   Their study published…

Analysis of the publication showing that cannabinoids prevent coronavirus-2 (SARS-CoV 2) infection
|

Analysis of the publication showing that cannabinoids prevent coronavirus-2 (SARS-CoV 2) infection

ByNikola NOWOTARSKA

Content of the publication:   A new study regarding the prevention of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection responsible for COVID-19 was published on January 10, 2022, in the scientific journal “The Journal of Natural Products”[1].  Researchers from the Oregon Health and Science University in Portland (USA) have demonstrated the potential of cannabinoids to…

Implementing ordinance for facilitated access to treatments with medicinal cannabis in the consultation process
|

Implementing ordinance for facilitated access to treatments with medicinal cannabis in the consultation process

ByCédric Heeb

Bern, 25.08.2021 – At its meeting on August 25, 2021, the Federal Council opened the consultation on the implementation of the amendment to the Narcotics Act (BetmG) passed by Parliament. The amendment is intended to facilitate access to treatments with therapeutic cannabis. In the future, a prescription will no longer require the granting of an exceptional authorization from the Federal Office of Public Health (FOPH). Cannabis for consumption purposes, on the other hand, will continue to be prohibited.

Medical Cannabis & Cannabinoid Regulation 2021

Medical Cannabis & Cannabinoid Regulation 2021

ByCédric Heeb

Trends and Developments The current regulatory environment surrounding cannabinoid-based products in Switzerland is unfortunately still marked by a high degree of uncertainty, due both to vague legislative requirements and heterogenous, sometimes arbitrary, enforcement. However, with the rise of public awareness of the general benefits of the cannabis plant as a result of the cannabidiol (CBD)…

Products containing cannabidiol (CBD) – overview 21.04.2021 updates

Products containing cannabidiol (CBD) – overview 21.04.2021 updates

ByCédric Heeb

Implementation guide by the technical platform for delimitation issues of the FOPH, the FSVO and Swissmedic Products containing cannabidiol (CBD) are gaining popularity in Switzerland. Unlike THC (tetrahydrocannabinol), CBD is not subject to the Narcotics Act because it does not produce a comparable psychoactive effect. However, this does not mean that CBD can simply be…

TRAINING : Medical Cannabis «From plant to patient»

TRAINING : Medical Cannabis «From plant to patient»

ByCédric Heeb

Visit the new educational event Cannabis as medicine – «From plant to patient». Implementation: 01.05.2021 – 30.06.2021 (on demand until 31.12.2021) Type: e-learning + online workshop (05.06.2021) Costs: CHF 350 Accreditations (among others): FPH: 100, accredited for continuing education FPH Offizin (role 1.2) and continuing education. SDV: requested SGAIM: 4 points for workshop + up…

Les essais pilotes sur la remise contrôlée de cannabis pourront débuter dès le mois de mai

Les essais pilotes sur la remise contrôlée de cannabis pourront débuter dès le mois de mai

ByCédric Heeb

Berne, 31.03.2021 – Le Conseil fédéral a adopté, lors de sa séance du 31 mars 2021, l’ordonnance portant sur les essais pilotes de remise contrôlée de cannabis à des fins non médicales. Le texte précise les conditions strictes dans lesquelles les études pourront être menées. L’objectif de ces essais est de fournir une base scientifique…

Applications for pilot trials on the non-medical use of cannabis can be submitted

Applications for pilot trials on the non-medical use of cannabis can be submitted

ByCédric Heeb

Starting from 15 May 2021, applications for pilot trials on the non-medical use of cannabis can be submitted to the FOPH. The aim of these trials is to provide a sound scientific basis for future decisions on the regulation of cannabis: Pilot trials on the controlled release of cannabis can start as early as May….

Radio: Hemp and Ecology – A local and sustainable medicine?

Radio: Hemp and Ecology – A local and sustainable medicine?

ByCédric Heeb

This week, in his radio programme “On va vers le beau“, Jonas Schneiter meets people who are working for sustainable solutions by developing different projects related to the production and transformation of hemp in Switzerland. Whether it is in the production of CBD, medicines, fashion or construction, he questions the role, the possibilities and the…